Revolutionizing Treatment: UK Grants Authorization to Vertex Pharmaceuticals and CRISPR Therapeutics for Groundbreaking CRISPR/Cas9 Gene-Edited Therapy
MHRA Approves CASGEVY™ for Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia, Marking a Milestone in Precision Medicine Date: 7 December 2023 Introduction: In a historic move that signals a new…